BR112016020304A2 - receptor antigênico quimérico (car) com domínios de ligação ao antígeno para a região constante beta do receptor de célula t - Google Patents

receptor antigênico quimérico (car) com domínios de ligação ao antígeno para a região constante beta do receptor de célula t

Info

Publication number
BR112016020304A2
BR112016020304A2 BR112016020304A BR112016020304A BR112016020304A2 BR 112016020304 A2 BR112016020304 A2 BR 112016020304A2 BR 112016020304 A BR112016020304 A BR 112016020304A BR 112016020304 A BR112016020304 A BR 112016020304A BR 112016020304 A2 BR112016020304 A2 BR 112016020304A2
Authority
BR
Brazil
Prior art keywords
car
constant region
binding domains
antigen binding
receptor
Prior art date
Application number
BR112016020304A
Other languages
English (en)
Other versions
BR112016020304B1 (pt
Inventor
PULÉ Martin
MACIOCIA Paul
Original Assignee
Ucl Business Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52649058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016020304(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB201403905A external-priority patent/GB201403905D0/en
Priority claimed from GB201416908A external-priority patent/GB201416908D0/en
Application filed by Ucl Business Plc filed Critical Ucl Business Plc
Publication of BR112016020304A2 publication Critical patent/BR112016020304A2/pt
Publication of BR112016020304B1 publication Critical patent/BR112016020304B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)

Abstract

a presente divulgação se refere a um receptor antigênico quimérico (car), que compreende um domínio de ligação ao antigénio que se liga seletivamente a região constante 1 beta de tcr (trbc1) ou trbc2; células; tal como células t que compreendem tal car; e o uso de tais células para o tratamento de um linfoma de células t ou leucemia em um sujeito
BR112016020304-6A 2014-03-05 2015-03-05 Receptor antigênico quimérico (car) e método in vitro para diagnosticar um linfoma de células t ou leucemia BR112016020304B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1403905.1 2014-03-05
GB201403905A GB201403905D0 (en) 2014-03-05 2014-03-05 Method
GB201416908A GB201416908D0 (en) 2014-09-25 2014-09-25 Method
GB1416908.0 2014-09-25
PCT/GB2015/050643 WO2015132598A1 (en) 2014-03-05 2015-03-05 Chimeric antigen receptor (car) with antigen binding domains to the t cell receptor beta constant region

Publications (2)

Publication Number Publication Date
BR112016020304A2 true BR112016020304A2 (pt) 2017-10-17
BR112016020304B1 BR112016020304B1 (pt) 2024-02-27

Family

ID=52649058

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016020304-6A BR112016020304B1 (pt) 2014-03-05 2015-03-05 Receptor antigênico quimérico (car) e método in vitro para diagnosticar um linfoma de células t ou leucemia

Country Status (23)

Country Link
US (2) US20170066827A1 (pt)
EP (2) EP3241561A1 (pt)
JP (5) JP6767872B2 (pt)
KR (3) KR102235201B1 (pt)
CN (3) CN112094353A (pt)
AU (3) AU2015225944B2 (pt)
BR (1) BR112016020304B1 (pt)
CA (1) CA2940564C (pt)
CL (4) CL2016002195A1 (pt)
CU (1) CU24475B1 (pt)
DK (1) DK3125934T3 (pt)
ES (1) ES2758173T3 (pt)
HU (1) HUE047641T2 (pt)
IL (3) IL278878B (pt)
MX (3) MX2016010856A (pt)
MY (1) MY173567A (pt)
PE (2) PE20211887A1 (pt)
PH (2) PH12016501646A1 (pt)
PL (1) PL3125934T3 (pt)
PT (1) PT3125934T (pt)
RU (3) RU2744046C2 (pt)
SG (3) SG10201906460PA (pt)
WO (1) WO2015132598A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11885807B2 (en) 2014-03-05 2024-01-30 Autolus Limited Method for depleting malignant T-cells
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
GB201403972D0 (en) 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
CN106795566B (zh) * 2014-10-03 2022-03-15 牛津大学科技创新有限公司 T细胞单型的分析
CA2937157A1 (en) * 2016-07-25 2018-01-25 Ucl Business Plc Protein-based t-cell receptor knockdown
AU2018219887A1 (en) 2017-02-08 2019-08-22 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
KR20190120782A (ko) 2017-02-20 2019-10-24 드래곤플라이 쎄라퓨틱스, 인크. Her2, nkg2d 및 cd16에 결합하는 단백질
MA49039A (fr) * 2017-04-04 2020-02-12 Hoffmann La Roche Nouvelles molécules bispécifiques de liaison à l'antigène capables de se lier spécifiquement à cd40 et à fap
GB201709203D0 (en) 2017-06-09 2017-07-26 Autolus Ltd Antigen-binding domain
WO2019025800A1 (en) * 2017-08-02 2019-02-07 Autolus Limited CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE
US20200231679A1 (en) * 2017-08-23 2020-07-23 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and a tumor-associated antigen
EP3684399A1 (en) 2017-12-29 2020-07-29 Cellectis Method for improving production of car t cells
WO2019129850A1 (en) * 2017-12-29 2019-07-04 Cellectis Off-the-shelf engineered cells for therapy
GB201800298D0 (en) * 2018-01-09 2018-02-21 Autolus Ltd Method
EP3765054A4 (en) * 2018-01-19 2022-01-12 The Trustees Of The University Of Pennsylvania COMPOSITIONS AND METHODS FOR TARGETING GAMMA DELTA T CELLS WITH CHIMERIC ANTIGEN RECEPTORS
AU2019218136A1 (en) 2018-02-08 2020-08-13 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
US20210283180A1 (en) * 2018-07-06 2021-09-16 The Arizona Board Of Regents On Behalf Of The University Of Arizona Car t cell therapy to target t cell specific cancers
WO2020018708A1 (en) * 2018-07-18 2020-01-23 The General Hospital Corporation Compositions and methods for treatment of t cell malignancies
GB201812650D0 (en) 2018-08-03 2018-09-19 Autolus Ltd Molecular assessment of TRBC usage
GB201817172D0 (en) 2018-10-22 2018-12-05 Autolus Ltd Antibody
US20220041718A1 (en) * 2018-10-31 2022-02-10 Autolus Limited Binding domain
WO2020156335A1 (zh) * 2019-01-29 2020-08-06 上海交通大学 一种嵌合抗原受体及其应用
CA3130754A1 (en) * 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
CN110317266A (zh) * 2019-07-17 2019-10-11 东北农业大学 三种scFv抗体、其编码基因及其在制备治疗或预防O型口蹄疫病制剂中的应用
WO2021188454A1 (en) * 2020-03-16 2021-09-23 Marengo Therapeutics, Inc. Engineered cell compositions and methods of use thereof
GB202004263D0 (en) 2020-03-24 2020-05-06 Autolus Ltd Antibody conjugate
GB202005216D0 (en) 2020-04-08 2020-05-20 Autolus Ltd Cell
EP4132962A1 (en) 2020-04-09 2023-02-15 Autolus Limited Molecule
GB202101491D0 (en) 2021-02-03 2021-03-17 Autolus Ltd Molecule
KR20230028242A (ko) * 2020-04-24 2023-02-28 마렝고 테라퓨틱스, 인크. T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도
CN111537735A (zh) * 2020-05-15 2020-08-14 江西赛基生物技术有限公司 抗体检测试剂盒以及在免疫分析方面的应用
CN111549044B (zh) * 2020-07-13 2020-10-23 北京市肿瘤防治研究所 靶向trbc1 car-t细胞的制备方法与应用
WO2022038115A1 (en) * 2020-08-18 2022-02-24 Medigene Immunotherapies Gmbh ENRICHMENT OF T CELLS USING AN ANTI-Cß ANTIBODY
KR20230074487A (ko) * 2020-08-26 2023-05-30 마렝고 테라퓨틱스, 인크. Trbc1 또는 trbc2를 검출하는 방법
US20220267415A1 (en) * 2021-02-17 2022-08-25 The Board Of Regents Of The University Of Texas System Multimeric sars-cov-2 binding molecules and uses thereof
WO2022177889A1 (en) * 2021-02-17 2022-08-25 The Johns Hopkins University Methods and materials for treating clonal t cell expansions
GB202112923D0 (en) * 2021-09-10 2021-10-27 Ucl Business Ltd Binding domain

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2088905A1 (en) * 1990-08-09 1992-02-10 Yongwon Choi Producing monoclonal antibodies against human t-cell receptor elements using recombinant dna vectors
US6790604B1 (en) * 1998-05-12 2004-09-14 Stefan A. Cohen Methods for identifying or diagnosing carcinoma cells with metastatic potential based on the measurement of lymphoid genes or their products in carcinoma cells
EP1497332A1 (en) * 2002-04-29 2005-01-19 GenPat77 Pharmacogenetics AG Bispecific antibody binding tcr and tirc7 and its use in therapy and diagnosis
RU2355703C2 (ru) * 2002-10-09 2009-05-20 Медиджен Лимитед Одноцепочечные рекомбинантные т-клеточные рецепторы
GB0304068D0 (en) * 2003-02-22 2003-03-26 Avidex Ltd Substances
US7741045B2 (en) * 2006-11-16 2010-06-22 General Electric Company Sequential analysis of biological samples
WO2009151628A2 (en) * 2008-06-12 2009-12-17 Gov't Of The Usa, As Represented By The Secretary, Department Of Health Human Services Monitoring tcr-b to determine hiv therapy and disease progression
JP2012501178A (ja) * 2008-08-26 2012-01-19 マクロジェニクス，インコーポレーテッド Ｔ細胞受容体抗体およびその使用方法
PT2519543T (pt) * 2009-12-29 2016-10-07 Emergent Product Dev Seattle Proteínas de ligação de heterodímero e suas utilizações
JP6000507B2 (ja) * 2010-09-30 2016-09-28 パナソニックヘルスケアホールディングス株式会社 診療情報登録装置
KR20230133410A (ko) * 2010-12-09 2023-09-19 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도
US10391126B2 (en) * 2011-11-18 2019-08-27 Board Of Regents, The University Of Texas System CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
KR102247979B1 (ko) * 2012-05-25 2021-05-04 셀렉티스 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
US10443100B2 (en) * 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
CA2959428A1 (en) * 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
IL302341A (en) * 2015-03-27 2023-06-01 Harvard College Modified T cells and methods for their preparation and use

Also Published As

Publication number Publication date
US20170066827A1 (en) 2017-03-09
CL2019001568A1 (es) 2019-08-16
JP2017143838A (ja) 2017-08-24
CN106068276A (zh) 2016-11-02
JP7149304B2 (ja) 2022-10-06
CL2018003096A1 (es) 2019-01-11
AU2015225944A1 (en) 2016-09-01
DK3125934T3 (da) 2020-02-03
IL278878A (en) 2021-01-31
JP2017510257A (ja) 2017-04-13
AU2019204925B2 (en) 2021-02-18
AU2015225944B2 (en) 2019-07-11
RU2018140694A (ru) 2018-12-10
NZ761848A (en) 2021-06-25
CU24475B1 (es) 2020-03-04
RU2016138421A (ru) 2018-04-05
KR20200027576A (ko) 2020-03-12
PH12020550203A1 (en) 2021-08-16
SG10201906461SA (en) 2019-09-27
CA2940564A1 (en) 2015-09-11
PE20211887A1 (es) 2021-09-22
KR20160127130A (ko) 2016-11-02
CN106068276B (zh) 2020-09-18
CA2940564C (en) 2021-06-29
KR102235201B1 (ko) 2021-04-05
MX2019013846A (es) 2020-02-24
CL2016002195A1 (es) 2017-05-19
IL278879A (en) 2021-01-31
KR102088082B1 (ko) 2020-03-11
MX2019013845A (es) 2020-02-24
NZ761844A (en) 2021-06-25
AU2019204921A1 (en) 2019-08-01
PL3125934T3 (pl) 2020-04-30
KR20200027577A (ko) 2020-03-12
JP2024074907A (ja) 2024-05-31
PH12016501646A1 (en) 2017-02-06
AU2019204921B2 (en) 2021-02-18
HUE047641T2 (hu) 2020-05-28
SG10201906460PA (en) 2019-09-27
US20170334998A1 (en) 2017-11-23
CN112094347A (zh) 2020-12-18
BR112016020304B1 (pt) 2024-02-27
EP3125934B1 (en) 2019-10-23
CN112094353A (zh) 2020-12-18
PE20170125A1 (es) 2017-03-16
SG11201606583VA (en) 2016-09-29
IL247110A0 (en) 2016-09-29
MY173567A (en) 2020-02-04
MX2016010856A (es) 2017-04-13
JP2021184773A (ja) 2021-12-09
RU2021101502A (ru) 2021-06-25
KR102235202B1 (ko) 2021-04-05
JP6767872B2 (ja) 2020-10-14
AU2019204921C1 (en) 2021-05-13
EP3241561A1 (en) 2017-11-08
JP6767931B2 (ja) 2020-10-14
AU2019204925A1 (en) 2019-08-01
RU2016138421A3 (pt) 2018-07-25
IL278878B (en) 2022-07-01
ES2758173T3 (es) 2020-05-04
WO2015132598A1 (en) 2015-09-11
RU2744046C2 (ru) 2021-03-02
JP2020099356A (ja) 2020-07-02
PT3125934T (pt) 2019-12-16
NZ723307A (en) 2021-06-25
EP3125934A1 (en) 2017-02-08
CL2019001567A1 (es) 2019-08-16

Similar Documents

Publication Publication Date Title
BR112016020304A2 (pt) receptor antigênico quimérico (car) com domínios de ligação ao antígeno para a região constante beta do receptor de célula t
CO2018010538A2 (es) Anticuerpos específicos del receptor de poliovirus humano (rvp)
MX2022003995A (es) Antigeno quimerico y receptores de celulas t y metodos de uso.
BR112017008914A2 (pt) método para tratar câncer, composição e uso da composição
EP3757120B8 (en) Co-stimulatory domains for use in genetically-modified cells
UY33647A (es) ?agentes de unión a cd33?.
BR112019021857A2 (pt) Métodos e composições de célula t aperfeiçoada
CO2017010190A2 (es) Terapias cd20, terapias cd22 y terapias de combinación con una célula que expresa un receptor quimérico de antígeno (car) de cd19
CR20190050A (es) Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos
ZA201707869B (en) Anti-ntb-a antibodies and related compositions and methods
UY35340A (es) Marcaje efectivo de leucemia humana usando células diseñadas con un receptor quimérico de antígeno anti-cd123
BR112017008945A2 (pt) Anticorpos anti-cs1 e conjugados fármaco- anticorpo
EP3611192A3 (en) T cell recruiting polypeptides based on tcr alpha/beta reactivity
BR112017020054A2 (pt) anticorpos para icos
GT201600171A (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblástica aguda
PH12020500225A1 (en) Anti- cd137 antibodies
BR112018067951A2 (pt) moléculas que se ligam a ilt7 e métodos de uso destas
EP3511422A3 (en) Methods and compositions for diagnosing, prognosing, and treating endometriosis
MX2016002027A (es) Nuevos anticuerpos anti receptores iib fc-gama y usos de los mismos.
MX2020009863A (es) Anticuerpos anti-cd137 para combinacion con anticuerpos anti-pd-l1.
BR112015030822A2 (pt) métodos e composições para reduzir a imunossupressão pelas células tumorais
AR100010A1 (es) Marcaje efectivo de leucemia humana usando células diseñadas con un receptor quimérico de antígeno anti-cd123
UA90680U (uk) Олігоетерсечовини з піридинієвими та сульфонатними групами як протонпровідні речовини

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Ipc: A61K 39/395 (2006.01), A61K 47/00 (2006.01), C07K

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: UCL BUSINESS LTD (GB)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: AUTOLUS LIMITED (GB)

B25G Requested change of headquarter approved

Owner name: AUTOLUS LIMITED (GB)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/03/2015, OBSERVADAS AS CONDICOES LEGAIS